Association of MAPT H1 subhaplotypes with neuropathology of lewy body disease
- PMID: 31234228
- PMCID: PMC7996001
- DOI: 10.1002/mds.27773
Association of MAPT H1 subhaplotypes with neuropathology of lewy body disease
Abstract
Background: Genetic variation at the microtubule-associated protein tau locus is associated with clinical parkinsonism. However, it is unclear as to whether microtubule-associated protein tau H1 subhaplotypes are associated with the burden of neuropathological features of Lewy body disease.
Objectives: To evaluate associations of microtubule-associated protein tau haplotypes with severity of Lewy body pathology and markers of SN neuronal loss in Lewy body disease cases.
Methods: Five hundred eighty-five autopsy-confirmed Lewy body disease cases were included. Six microtubule-associated protein tau variants (rs1467967, rs242557, rs3785883, rs2471738, rs8070723, and rs7521) were genotyped to define common microtubule-associated protein tau haplotypes. Lewy body counts were measured in five cortical regions. Ventrolateral and medial SN neuronal loss were assessed semiquantitatively. Nigrostriatal dopaminergic degeneration was quantified by image analysis of tyrosine hydroxylase immunoreactivity in the dorsolateral and ventromedial putamen.
Results: The common microtubule-associated protein tau H2 haplotype did not show a strong effect on pathological burden in Lewy body disease. The rare H1j haplotype (1.3%) was significantly associated with a lower dorsolateral putaminal tyrosine hydroxylase immunoreactivity (and therefore greater dopaminergic degeneration) compared to other microtubule-associated protein tau haplotypes (P = 0.0016). Microtubule-associated protein tau H1j was also nominally (P ≤ 0.05) associated with a lower ventromedial putaminal tyrosine hydroxylase immunoreactivity (P = 0.010), but this did not survive multiple testing correction. Other nominally significant associations between microtubule-associated protein tau H1 subhaplotypes and neuropathological outcomes were observed.
Conclusions: A rare microtubule-associated protein tau H1 subhaplotype (H1j) may be associated with more severe putaminal dopaminergic degeneration in Lewy body disease cases. Microtubule-associated protein tau H1j has been associated previously with an increased risk of PD, and therefore our exploratory findings provide insight into the mechanism by which H1j modulates PD risk. © 2019 International Parkinson and Movement Disorder Society.
Keywords: Lewy body disease; MAPT; genetics; haplotype; neuropathology.
© 2019 International Parkinson and Movement Disorder Society.
Conflict of interest statement
Similar articles
-
MAPT subhaplotypes in corticobasal degeneration: assessing associations with disease risk, severity of tau pathology, and clinical features.Acta Neuropathol Commun. 2020 Dec 7;8(1):218. doi: 10.1186/s40478-020-01097-z. Acta Neuropathol Commun. 2020. PMID: 33287913 Free PMC article.
-
Regional analysis and genetic association of nigrostriatal degeneration in Lewy body disease.Mov Disord. 2017 Nov;32(11):1584-1593. doi: 10.1002/mds.27184. Epub 2017 Sep 26. Mov Disord. 2017. PMID: 28949048 Free PMC article.
-
An evaluation of the impact of MAPT, SNCA and APOE on the burden of Alzheimer's and Lewy body pathology.J Neurol Neurosurg Psychiatry. 2012 Apr;83(4):424-9. doi: 10.1136/jnnp-2011-301413. Epub 2012 Jan 30. J Neurol Neurosurg Psychiatry. 2012. PMID: 22291217 Free PMC article.
-
MAPT haplotype H1G is associated with increased risk of dementia with Lewy bodies.Alzheimers Dement. 2016 Dec;12(12):1297-1304. doi: 10.1016/j.jalz.2016.05.002. Epub 2016 Jun 7. Alzheimers Dement. 2016. PMID: 27287057 Free PMC article. Review.
-
Meta-analysis of the association between variants in MAPT and neurodegenerative diseases.Oncotarget. 2017 Jul 4;8(27):44994-45007. doi: 10.18632/oncotarget.16690. Oncotarget. 2017. PMID: 28402959 Free PMC article. Review.
Cited by
-
A Specific Diplotype H1j/H2 of the MAPT Gene Could Be Responsible for Parkinson's Disease with Dementia.Case Rep Genet. 2020 Dec 3;2020:8813344. doi: 10.1155/2020/8813344. eCollection 2020. Case Rep Genet. 2020. PMID: 33343949 Free PMC article.
-
MAPT allele and haplotype frequencies in Nigerian Africans: population distribution and association with Parkinson's disease risk and age at onset.medRxiv [Preprint]. 2023 Mar 24:2023.03.24.23287684. doi: 10.1101/2023.03.24.23287684. medRxiv. 2023. Update in: Parkinsonism Relat Disord. 2023 Aug;113:105517. doi: 10.1016/j.parkreldis.2023.105517. PMID: 36993627 Free PMC article. Updated. Preprint.
-
PLCG2 protective variant p.P522R modulates tau pathology and disease progression in patients with mild cognitive impairment.Acta Neuropathol. 2020 Jun;139(6):1025-1044. doi: 10.1007/s00401-020-02138-6. Epub 2020 Mar 12. Acta Neuropathol. 2020. PMID: 32166339 Free PMC article.
-
Pathological Influences on Clinical Heterogeneity in Lewy Body Diseases.Mov Disord. 2020 Jan;35(1):5-19. doi: 10.1002/mds.27867. Epub 2019 Oct 29. Mov Disord. 2020. PMID: 31660655 Free PMC article. Review.
-
Variants in PPP2R2B and IGF2BP3 are associated with higher tau deposition.Brain Commun. 2020 Sep 26;2(2):fcaa159. doi: 10.1093/braincomms/fcaa159. eCollection 2020. Brain Commun. 2020. PMID: 33426524 Free PMC article.
References
-
- McCann H, Stevens CH, Cartwright H, Halliday GM. α-Synucleinopathy phenotypes. Parkinsonism Relat Disord 2014;20(Suppl 1):S62–S67. - PubMed
-
- Lippa CF, Duda JE, Grossman M, et al. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 2007;68:812–819. - PubMed
-
- Trinh J, Farrer M. Advances in the genetics of Parkinson disease. Nat Rev Neurol 2013;9:445–454. - PubMed